

2024 Top 10 drugs with the Most Prescriptions

Drug Name	Therapeutic Class	Prescriptions
Atorvastatin calcium	Antihyperlipidemics	185,385
Levothyroxine sodium	Thyroid agents	168,754
Lisinopril	Antihypertensives	164,576
Amphetamine dextroamphetamine	ADHD / anti-narcolepsy/ anti obesity/anorexiant	151,018
Metformin HC	Antidiabetics	146,749
Bupropion HCl	Antidepressants	145,453
Fluzone	Vaccines	131,030
Sertraline HCl	Antidepressants	125,994
Losartan	Angiotensin receptor blockers	125,620
Albuterol sulfate	Anti-asthmatic/bronchodilator agents	119,330

2024 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/20241121-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2024.pdf#page=43>

2024 Top 10 drugs with Highest Cost

Drug name	Therapeutic class	Total annual plan spending
Humira	Analgesics/anti-inflammatory	\$53,267,675
Keytruda	Antineoplastics and adjunctive therapies	\$37,816,382
Stelara	Dermatologicals	\$31,156,649
Biktarvy	Antivirals	\$26,933,839
Skyrizi	Dermatologicals	\$25,622,754
Entyvio	Gastrointestinal agent	\$21,299,837
Enbrel	Analgesics/anti-inflammatory	\$21,147,861
Cosentyx	Dermatologicals	\$20,464,979
Ozempic	Antihyperglycemic	\$18,232,971
Dupixent	interleukin inhibitors	\$17,124,535

2024 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/20241121-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2024.pdf#page=43>

2024 Top 10 drugs with the Greatest Increase

Drug name	Therapeutic class	Year-over-year increase
Keytruda	Antineoplastics and adjunctive therapies	\$13,569,234
Skyrizi	Dermatologicals	\$10,452,298
Ozempic	Antidiabetics	\$8,708,006
Comirnaty	Vaccine	\$5,964,667
Pevnar	Vaccine	\$4,735,807
Dupixent	Dermatologicals	\$4,510,445
Stelara	Dermatologicals	\$4,315,271
Verzenio	Antineoplastic and adjunctive therapies	\$3,716,818
Jardiance	Antidiabetic	\$2,666,754
Entyvio	Gastrointestinal agents – miscellaneous	\$2,327,492

2024 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/20241121-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2024.pdf#page=43>